>>> Novo Nordisk : Announces U.S. Launch of NovoFine Plus, a New Pen Needle for

Announces U.S. Launch of NovoFine Plus, a New Pen Needle for Patients with Diabetes

announced the availability of its shortest and thinnest pen needle, NovoFinePlus, in the United States. NovoFinePlus is a universal needle that works with all currently available insulin and some GLP-1 receptor agonist pens. The Food and Drug Administration (FDA) cleared the 510(k) application for NovoFinePlus earlier this year.

Pen needles are an integral part of the treatment experience for patients who rely on injectable therapies. Novo Nordisk is currently the only company that offers all components of the delivery system, with integrated development of insulin, needles, and pens. NovoFinePlus joins an entire family of Novo Nordisk pen needles, including NovoTwist32G Tip, NovoFine32G Tip and NovoFineAutocover30G.

>>> Hyatt Hotels misses by $0.06, misses on revs (62.00)

Hyatt Hotels misses by $0.06, misses on revs

Reports Q3 (Sep) earnings of $0.20 per share, excluding non-recurring items, $0.06 worse than the Capital IQ Consensus Estimate of $0.26; revenues rose 7.6% year/year to $1.1 bln vs the $1.12 bln consensus.

Comparable systemwide RevPAR increased 7.6% (8.0% excluding the effect of currency) in 3Q14 compared to 3Q13.


--> Watch MAR US - look intersting short on the chart

(BFW) Coca-Cola LBO Approach May Be Worth $90/Shr, Nomura Says

Coca-Cola LBO Approach May Be Worth $90/Shr, Nomura Says
2014-10-29 11:43:01.372 GMT


By Heather Burke
Oct. 29 (Bloomberg) -- Coca-Cola’s initiatives announced
last wk are moving in right direction, needs to accelerate,
Nomura says in note; an LBO may have some attraction.
* Reiterates buy, raises PT to $54 vs $51.50 (~33% upside)
* LBO approach possible if co. doesn’t quickly implement plans
to improve margins
* An LBO could more “aggressively” address value creation,
and could value co. at $90/shr, more than rationalize paying
25% premium on current stock price
* Nomura’s analysis of finance structure for LBO finds
estimated FCF for equity investment in “New Coke” under an
LBO (which they estimate at $50b) would be more than FCF
currently earned by KO shareholders
* NOTE: Coca-Cola fell 6% on Oct. 21 as co. said sees yr EPS
below L-T target; cost-cutting plan fails to placate
investors
* NOTE: Oct. 2, Warren Buffett (largest holder with 9.1%
stake) said Coke’s new plan make a lot of sense, still feels
good about KO investment

For Related News and Information:
First Word scrolling panel: FIRST<GO>
First Word newswire: NH BFW<GO>

To contact the reporter on this story:
Heather Burke in London at +44-20-7673-2044 or
hburke2@bloomberg.net
To contact the editor responsible for this story:
James Ludden at +44-20-7673-2645 or
jludden@bloomberg.net

>>> Waste Mgmt beats by $0.04, misses on revs; guides FY14 EPS above consensus

Waste Mgmt beats by $0.04, misses on revs; guides FY14 EPS above consensus

Reports Q3 (Sep) earnings of $0.72 per share, excluding non-recurring items, $0.04 better than the Capital IQ Consensus Estimate of $0.68; revenues fell 0.5% year/year to $3.6 bln vs the $3.66 bln consensus.
  • "Once again, our strong yield and cost controls delivered growth in our traditional solid waste business as income from operations grew $13 mln and income from operations margin rose by 60bps compared to the third quarter of 2013 results..."
Co issues upside guidance for FY14, sees EPS of $2.41 from prior guidance of $2.35, excluding non-recurring items, vs. $2.36 Capital IQ Consensus Estimate.
  • "We are confident that we can meet the analysts' fourth quarter consensus of $0.60 of adjusted earnings per diluted share. That would lead to full year adjusted earnings per diluted share of $2.41, $0.06 above the high end of our previous range. Cash flow has also been strong through the first three quarters, and we expect that we will also exceed the $1.5 billion high end of our free cash flow guidance."

>>> Hess beats by $0.18, beats on revs --> +2.77% pre open (very low volume)

Hess beats by $0.18, beats on revs

Reports Q3 (Sep) earnings of $1.24 per share, $0.18 better than the Capital IQ Consensus Estimate of $1.06; revenues rose 3.2% year/year to $2.8 bln vs the $2.6 bln consensus.
  • Oil and gas production was 318,000 barrels of oil equivalent per day (boepd) in the third quarter of 2014, compared with 310,000 boepd in the year-ago quarter. Pro forma production was 314,000 boepd in the third quarter of 2014, up 17 percent from 269,000 boepd in 2013
  • Lower realized crude oil selling prices and higher depreciation expense in the third quarter of 2014 were the primary drivers for the decrease in adjusted net income. However, adjusted net income per share in the third quarter of 2014 increased over the third quarter of last year due to an 11 percent decrease in the weighted average number of diluted shares outstanding primarily as a result of the Corporation's stock repurchase program.

>>> US Early premarket gappers

Early premarket gappers

Gapping up: ZLTQ +10.9%, ICAD +9.9%, X +8%, EXTR +7.6%, ARNA +5.7%, RFMD +5.2%, TQNT +4.7%, AKS +4.4%, EGL +4.2%, EGL +4.2%, IPHI +3.7%, MRCY +3.6%, AMC +3.5%, SWI +3.5%, DLR +3.3%, SPF +3%, ULTI +3%, JKS +2.9%, IDT +2.6%, XCO +2.5%, GPRE +2.5%, SANM +1.9%, CYBR +1.8%, PLUG +1.8%, LECO +1.7%, WES +1.7%, CNHI +1.5%, SKYW+1.5%, CAP +1.3%, EXP +1.2%, AFL +1.2%, AMZN +1%, HSY +1%, WYNN +0.9%

Gapping down: INVN -24.6%, IBIO -16.4%, KEYW -14.4%, MTSC -14.4%, XOOM -12.6%, HIVE -11.5%, STM -10.5%, AMCC -9.2%, SM -8%, FB -7.8%, SNY -4.9%, TRUE -4.4%, NVMI -4.1%, PNRA -2.6%, GILD -2.3%, SGYP -1.9%, VNDA -1.8%, VRTX -1.8%, AZPN -1.8%, OI -1.8%, HTS -1.6%, PRU -1.5%, WDC -1.3%, TRN -1.2%, GAIN -1.2%, EA -1.1%, ARCP -1.1%, FISV -1%,WEC -1%, TEL -0.9%, APA -0.8%, TWTR -0.7%

>>> Praxair reports EPS in-line, revs in-line; guides Q4 EPS below consensus

Praxair reports EPS in-line, revs in-line; guides Q4 EPS below consensus

Reports Q3 (Sep) earnings of $1.62 per share, in-line with the Capital IQ Consensus Estimate of $1.62; revenues rose 4.3% year/year to $3.14 bln vs the $3.16 bln consensus.
  • Organic sales grew 5% from higher volumes, including new project start-ups, in North America, South America and Asia, and higher price across all operating segments. By end-market, sales growth was strongest for manufacturing, food and beverage, healthcare and metals customers.
Co issues downside guidance for Q4, sees EPS of $1.53-1.60 vs. $1.65 Capital IQ Consensus Estimate.
  • "Volume growth was mixed. In North America, our U.S. and Canadian businesses grew quite well, while sales to energy-related customers in Mexico remained weak. European volumes grew modestly across most countries. Asia experienced slowing volume growth in China, while India volumes were strong. Praxair Brazil delivered growth in a negative industrial production environment driven by new applications and growth in healthcare and food and beverage end-markets.

I